js203
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 22, 2022 (NCT05618327)
Timeline
Indications
Studied for
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD20BINDING AGENT
MS4A1 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07081022 | Phase 2 | Aug 17, 2025 | Shanghai Junshi Bioscience Co.,Ltd. |
| NCT05618327 | Phase 1 | Nov 22, 2022 | Peking University, Shanghai Junshi Bioscience Co.,Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Junshi Bioscience Co.,Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1